Citations 2
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Pappo, Alberto S. , Acquazzino, Melissa , Barnett, Marie , Casey, Robert, Choo, Sun , Dinner, Shira, Fair, Douglas , Federman, Noah , Folbrecht, Jeanelle , Gandhi, Shipra , Germann, Julie N. , Goldsby, Robert E. , Hayashi, Robert J. , Huang, Mary , Jacobs, Linda A. , Lee‐Miller, Cathy , Link, Michael P., Lustberg, Maryam B. , Malogolowkin, Marcio H., Oeffinger, Kevin C. , Pratilas, Christine A. , Mehren, Margaret von , Yeager, Nicholas D. , Hang, Lisa, von Mehren, Margaret , Lustberg, Maryam , Bhatia, Smita , Allen‐Rhoades, Wendy , Borinstein, Scott C. , Chugh, Rashmi , Ermoian, Ralph P. , Huang, Alex Yee-Chen , Livingston, J. Andrew , Reed, Damon R. , Skiles, Jodi L. , Montgomery, Sarah E.
Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 851-880
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Bender, Julia Glade , Blaney, Susan M. , Baruchel, Sylvain , Ahern, Charlotte H., Ingle, Ashish M., Chen, Alice P. , Weigel, Brenda J. , Adamson, Peter C. , Borinstein, Scott C. , Reid, Joel M. , Yamashiro, Darrell J. , Park, Julie R. , Glade-Bender, Julia
Clinical Cancer Research | July 13, 2012 | Volume: 18 | Issue: 18 | Pages: 5081-5089
Abstract Purpose: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept. Experimental Design: Cohorts of three to six children with refractory solid tumors received aflibercept intravenously over 60 minutes every 14 days, at 2.0, 2.5, or 3.0 mg/kg/dose. PK sampling and analysis of peripheral blood biomarkers were conducted with the initial dose. Results: Twenty-one eligible patients were enrolled; 18 were fully evaluable for toxicity. One of six patients receiving 2.0 mg/kg/dose developed dose-limiting intratumoral hemorrhage and two of six receiving 3.0 mg/kg/dose developed either dose-limiting tumor pain or tissue necrosis. None of the six patients receiving 2.5 mg/kg/dose developed DLTs, defining this as the MTD. The most common non-DLTs were hypertension and fatigue. Three patients with hepatocellular carcinoma, hepatoblastoma and clear cell sarcoma had stable disease for >13 weeks. At the MTD, the ratio of free-to-bound aflibercept serum concentration was 2.10 on day 8 but only 0.44 by day 15. A rapid decrease in VEGF (P < 0.05) and increase in placental growth factor (PlGF; P < 0.05) from baseline was observed in response to aflibercept by day 2. Conclusions: The aflibercept MTD in children of 2.5 mg/kg/dose every 14 days is lower than the adult recommended dose of 4.0 mg/kg. This dose achieves, but does not sustain, free aflibercept concentrations in excess of bound. Tumor pain and hemorrhage may be evidence of antitumor activity but were dose-limiting. Clin Cancer Res; 18(18); 5081–9. ©2012 AACR.